Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an 'Overweight' rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) but lowered the price target from $90 to $84.
November 03, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an 'Overweight' rating on Ultragenyx Pharmaceutical but lowered the price target from $90 to $84.
The news is directly about Ultragenyx Pharmaceutical (RARE). While the 'Overweight' rating suggests that Morgan Stanley expects the stock to outperform, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100